Innovative Research & Solution for Treatment of Diabetic Complications
OXO TS is a German drug development company in advanced stage with goal to treat root cause of diabetic complications
Our Products
OXO TS is the owner of the two chlorite-based drug products: Oxovasin® and Immunokine®
Oxovasin® is a topical solution for chronic wounds. The drug is approved and marketed in Germany and Thailand.
Immunokine® is an intravenous infusion solution for adjunct therapy for treatment of post-radiation cystitis and diabetic foor ulcer. The drug is currently approved and marketed only in Thailand.
Oxovasin®
Topical solution for chronic wounds
Immunokine®
i.v. solution for diabetic foot ulcers
Project DKD
WF10 is a chlorite-based solution administered by means of i.v. infusion. It represents a redox-active drug with immune-modulatory and inflammation-resolving properties.
Our phase-II multi-centric clinical trials, initially in Southeast Asia and subsequently in Europe, aim to demonstrate efficiency of WF10 in treatment of advanced Diabetic Kidney Disease (DKD), corresponding to CKD stage 3a-4.
WF10-therapy represents a new strategy and a risk-lowering therapy for the causal treatment of DKD.